LIVE WEBINAR: Wednesday, April 21, 2021, 12:00 PM – 1:00 PM Eastern Time

Dissecting the Decision: Investigator Perspectives on Key Issues in the Management of Common Cancers

13th Annual Oncology Grand Rounds NCPD Webinar Series

Acute Myeloid Leukemia

Register for the REPLAY of this event taking place on May 5

Register for this complimentary event with the “Register” button above,
which will take you to our Zoom registration page.

Faculty
Courtney D DiNardo, MD, MSCE
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Eytan M Stein, MD
Assistant Attending Physician
Director, Program for Drug Development in Leukemia
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Nurse Case Presentations By
Ilene Galinsky, NP
Senior Adult Leukemia Program Research Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Sonia Glennie, ARNP, MSN, OCN
Swedish Cancer Institute Center for Blood Disorders
Seattle, Washington

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AbbVie Inc and Genentech, a member of the Roche Group.

Wednesday, April 21, 2021
12:00 PM – 1:00 PM Eastern Time
Live NCPD-accredited webinar

Topics to Be Discussed

  • Overview of the incidence and prognosis of acute myeloid leukemia (AML) in adults; patient signs and symptoms at presentation and the diagnostic process; key patient- and disease-specific factors affecting patient care
  • Review of the indications for treatment, goals of therapy and general therapeutic approach for patients with newly diagnosed AML: Induction, consolidation and maintenance therapy and hematopoietic stem cell transplantation versus palliative therapy
  • Role of cytogenetics and molecular profiling in prognosis, risk stratification and treatment decision-making for AML; spectrum and incidence of actionable mutations
  • Current landscape of approved therapies for AML, including considerations for dosing, administration and the monitoring and management of side effects
  • Treatment approaches for patients who are medically fit and for those who are ineligible for intensive induction therapy: Efficacy and toxicity of standard “7 + 3” induction chemotherapy-containing regimens, hypomethylating agents (eg, azacitidine, decitabine), low-dose cytarabine, venetoclax-based regimens and best supportive care
  • Available agents targeting FLT3 ITD and TKD mutations (eg, sorafenib, midostaurin, gilteritinib): Mechanism of action, effectiveness and incorporation into the treatment of newly diagnosed and relapsed disease; dosing, side effects and toxicity management
  • Available agents targeting IDH1 and IDH2 mutations (eg, ivosidenib and enasidenib, respectively): Mechanism of action, effectiveness and incorporation into the treatment of AML; identification and management of tumor lysis syndrome, differentiation syndrome and other common toxicities
  • Newly approved agents: Mechanism of action, efficacy, and the spectrum, incidence and management of associated adverse events

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of acute myeloid leukemia (AML).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities in patients with AML, and understand the rationale for diagnostic testing.
  • Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of AML.
  • Recognize the FDA approval of venetoclax in combination with a hypomethylating agent or low-dose cytarabine for patients with newly diagnosed AML who are not eligible for intensive therapy, and discern how these regimens can be optimally integrated into nonresearch care algorithms.
  • Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to counsel patients with AML with FLT3 mutations regarding personalized treatment recommendations and research opportunities.
  • Develop an understanding of the available data with and current role of available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and IDH1 or 2 mutations.
  • Appreciate the mechanism of action, published clinical research and FDA-endorsed indication for CPX-351 for patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be optimally integrated into nonresearch care algorithms.
  • Consider Phase III data documenting the efficacy of CC-486 as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and appreciate how this novel strategy can be appropriately employed in clinical care.
  • Formulate a treatment algorithm for patients with lower- and higher-risk myelodysplastic syndromes (MDS), considering patient and disease-related factors, including cytogenetic abnormalities.
  • Understand the recent FDA approval of the combination of decitabine and cedazuridine for intermediate- and high-risk MDS, and identify patients for whom treatment with this novel approach may be appropriate.
  • Describe the biologic rationale for and mechanism of action of luspatercept in the treatment of anemia secondary to MDS, and recognize how this agent can be appropriately integrated into clinical practice.
  • Recall promising agents and combination strategies under investigation for AML and MDS, and counsel appropriately selected patients regarding clinical trial enrollment.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1 contact hour is provided by RTP.

This activity is awarded 1 ANCC pharmacotherapeutic contact hour.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. Credit form links will be emailed to participating nurses within 3 business days of the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2021/AML/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr DiNardoAdvisory Committee: Foghorn Therapeutics, Gilead Sciences Inc, Immune-Onc Therapeutics Inc, Novartis, Takeda Oncology; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Cleave Therapeutics, Daiichi Sankyo Inc, Immune-Onc Therapeutics Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Scientific Advisory Board with Stock Options: Notable Labs. Dr SteinAdvisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Ono Pharmaceutical Co Ltd, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Bayer HealthCare Pharmaceuticals, BioTheryX Inc, Bristol-Myers Squibb Company, Celgene Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Prelude Therapeutics, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc.

CONTRIBUTING NURSESMs Galinsky had no relevant conflicts of interest to disclose. The following nurse practitioner reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ms GlennieSpeakers Bureau: Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

RTP NCPD Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc and Genentech, a member of the Roche Group.